NCT05056194View on ClinicalTrials.gov

Valiloxybate (XW10172 MR) Efficacy and Safety Parkinson's Disease Study

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

November 1, 2021

Primary Completion Date

November 1, 2022

Study Completion Date

November 1, 2022

Conditions

Parkinson DiseaseExcessive Daytime Somnolence

Interventions

DRUG

Valiloxybate

XW10172 MR Granules for Oral Suspension

OTHER

Placebo

Placebo Granules for Oral Suspension

Sponsors

Lead Sponsor

All Listed Sponsors

lead

XWPharma

INDUSTRY